Clustering-based COPD subtypes have distinct longitudinal outcomes and multi-omics biomarkers.
Clustering-based COPD subtypes have distinct longitudinal outcomes and multi-omics biomarkers.
复制标题
DOI:
10.1136/bmjresp-2021-001182
复制
发表时间:
2022-08
影响因子:
4.1
通讯作者:
中科院分区:
文献类型:
--
作者:
Chronic obstructive pulmonary disease (COPD) can progress across several domains, complicating the identification of the determinants of disease progression. In our previous work, we applied k-means clustering to spirometric and chest radiological measures to identify four COPD-related subtypes: ‘relatively resistant smokers (RRS)’, ‘mild upper lobe-predominant emphysema (ULE)’, ‘airway-predominant disease (AD)’ and ‘severe emphysema (SE)’. In the current study, we examined the associations of these subtypes to longitudinal COPD-related health measures as well as blood transcriptomic and plasma proteomic biomarkers. We included 8266 non-Hispanic white and African-American smokers from the COPDGene study. We used linear regression to investigate cluster associations to 5-year prospective changes in spirometric and radiological measures and to gene expression and protein levels. We used Cox-proportional hazard test to test for cluster associations to prospective exacerbations, comorbidities and mortality. The RRS, ULE, AD and SE clusters represented 39%, 15%, 26% and 20% of the studied cohort at baseline, respectively. The SE cluster had the greatest 5-year FEV1 (forced expiratory volume in 1 s) and emphysema progression, and the highest risks of exacerbations, cardiovascular disease and mortality. The AD cluster had the highest diabetes risk. After adjustments, only the SE cluster had an elevated respiratory mortality risk, while the ULE, AD and SE clusters had elevated all-cause mortality risks. These clusters also demonstrated differential protein and gene expression biomarker associations, mostly related to inflammatory and immune processes. COPD k-means subtypes demonstrate varying rates of disease progression, prospective comorbidities, mortality and associations to transcriptomic and proteomic biomarkers. These findings emphasise the clinical and biological relevance of these subtypes, which call for more study for translation into clinical practice. NCT00608764.
登录
查看更多内容
影响因子:
5.8
作者:
Ford ES;Wheaton AG;Mannino DM;Presley-Cantrell L;Li C;Croft JB
通讯作者:
Croft JB
影响因子:
3.7
作者:
Arostegui I;Esteban C;García-Gutierrez S;Bare M;Fernández-de-Larrea N;Briones E;Quintana JM;IRYSS-COPD Group
通讯作者:
IRYSS-COPD Group
影响因子:
3.1
作者:
Hersh CP;Make BJ;Lynch DA;Barr RG;Bowler RP;Calverley PM;Castaldi PJ;Cho MH;Coxson HO;DeMeo DL;Foreman MG;Han MK;Harshfield BJ;Hokanson JE;Lutz S;Ramsdell JW;Regan EA;Rennard SI;Schroeder JD;Sciurba FC;Steiner RM;Tal-Singer R;van Beek E Jr;Silverman EK;Crapo JD;COPDGene and ECLIPSE Investigators
通讯作者:
COPDGene and ECLIPSE Investigators
DOI:
10.1164/ajrccm.159.3.9805067
发表时间:
1999-03-01
影响因子:
24.7
作者:
Coxson, HO;Rogers, RM;Hogg, JC
通讯作者:
Hogg, JC
DOI:
10.1164/rccm.201105-0831oc
发表时间:
2011-11-01
影响因子:
24.7
作者:
Casanova, Ciro;de Torres, Juan P.;Celli, Bartolome R.
通讯作者:
Celli, Bartolome R.